Primary systemic anaplastic large cell lymphoma in a single Korean institution: Clinical characteristics and treatment outcome

Journal of Korean Medical Science

Volumn 21, Issue 4, 2006, Pages 633-638

  Sook, Ryun Park ^a   Ji, Yeon Baek ^a   Kim, Dong Wan ^a   Im, Seok Ah ^a   Kim, Tae You ^a   Bang, Yung Jue ^a   Noe, Kyeong Kim ^a   Yoon, Kyung Jeon ^a   Chul, Woo Kim ^a   Dae, Seog Heo ^a  

^a Seoul National University   (South Korea)

Author keywords

Anaplastic lymphoma kinase; CD30 Positive Anaplastic Large Cell Lymphoma; Drug therapy; Lymphoma, Large Cell, Ki 1

Indexed keywords

EID: 33746904677     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2006.21.4.633     Document Type: Article

References (31)

1. Melnyk A, Rodriquez A, Pugh WC, Cabanillas F. Evaluation of the revised European-American lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma. Blood 1997; 89: 4514-20.
2. The Non-Hodgkin's lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin's lymphoma. Blood 1997; 89: 3909-18.
3. Shih LY, Liang DC. Non-Hodgkin's lymphomas in Asia. Hematol Oncol Clin North Am 1991; 5: 983-1001.
4. Ko YH, Kim CW, Park CS, Jang HK, Lee SS, Kim SH, Ree HJ, Lee JD, Kim SW, Huh JR. REAL classification of malignant lymphomas in the Republic of Korea. Cancer 1998; 83: 806-12.
5. Kang YK, Kim BS, Kim TW, Ryu MH, Lee SS, Ryoo BY, Kim TY, Im YH, Lee KH, Huh J, Heo DS, Bang YJ, Kim C, Lee JS, Kim BK, Kim WK, Kim SH, Kim NK. Clinicopathologic characteristics of Korean non-Hodgkin's lymphomas based on REAL classification. J Korean Cancer Assoc 1999; 31: 641-52.
6. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC, Grogan TM, Isaacson PG, Knowles DM, Mason DY, Muller-Hermelink HK, Pileri SA, Piris MA, Ralfkiaer E, Warnke RA. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-92.
7. Rimokh R, Magaud JP, Berger F, Samarut J, Coiffier B, Germain D, Mason DY. A translocation involving a specific breakpoint (q35) on chromosome 5 is characteristic of anaplastic large cell lymphoma (Ki-1 lymphoma). Br J Haematol 1989; 71: 31-6.
8. Falini B, Pileri S, Zinzani PL, Carbone A, Zagonel V, Wolf-Peeters C, Verhoef G, Menestrina F, Todeschini G, Paulli M, Lazzarino M, Giardini R, Aiello A, Foss HD, Araujo I, Fizzotti M, Pelicci PG, Flenghi L, Martelli MF, Santucci A. ALK+ lymphoma: clinico-pathological findings and outcome. Blood 1999; 93: 2697-706.
9. Gascoyne RD, Aoun P, Wu D, Chhanabhai M, Skinnider BF, Greiner TC, Morris SW, Connors JM, Vose JM, Viswanatha DS, Coldman A, Weisenburger DD. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 1999; 93: 3913-21.
10. Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001.
11. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the committee on Hodgkin's disease staging classification. Cancer Res 1971; 31: 1860-1.
12. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA Jr, Miller TP. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002-6.
13. Coleman M, Armitage JO, Gaynor M, McDermott D, Weisenburger DD, Adler K, Beshevkin M, Silver RT, Reisman AM, Pasmantier MW. The COPBLAM programs: Evolving chemotherapy concepts in large cell lymphoma. Semin Hematol 1988; 25: 23-33.
14. World Health Organization: WHO handbook for reporting results of cancer treatment. WHO offset publication no. 48. World Health Organization, Geneva, Switzerland.
15. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958; 53: 457-81.
16. Shulman LN, Frisard B, Antin JH, Wheeler C, Pinkus G, Magauran N, Mauch P, Nobles E, Mashal R, Canellos G. Primary Ki-1 anaplastic large-cell lymphoma in adults: Clinical characteristics and therapeutic outcome. J Clin Oncol 1993; 11: 937-42.
17. Zinzani PL, Bendandi M, Martelli M, Falini B, Sabattini E, Amadori S, Gherlinzoni F, Martelli MF, Mandelli F, Tura S, Pileri SA. Anaplastic large-cell lymphoma: Clinical and prognostic evaluation of 90 adult patients. J Clin Oncol 1996; 14: 955-62.
18. Clavio M, Rossi E, Truini M, Carrara P, Ravetti JL, Spriano M, Vimercati AR, Santini G, Canepa L, Pierri I, Celesti L, Miglino M, Castellaneta A, Damasio E, Gobbi M. Anaplastic large cell lymphoma: A clinicopathologic study of 53 cases. Leuk Lymphoma 1996; 22: 319-27.
19. Longo G, Fiorani C, Sacchi S, Callea V, Lombardo M, Federico M, Stelitano C, Angrilli F, Vallisa D, Gobbi PG, Ilariucci F, Frassoldati A, Petrini M, Silingardi V. Clinical characteristics, treatment outcome and survival of 36 adult patients with primary anaplastic large cell lymphoma. Haematologica 1999; 84: 425-30.
20. Tilly H, Gaulard P, Lepage E, Dumontet C, Diebold J, Plantier I, Berger F, Symann M, Petrella T, Lederlin P, Briere J. Primary anaplastic large-cell lymphoma in adults. Clinical presentation, immunophenotype, and outcome. Blood 1997; 90: 3727-34.
21. Pileri S, Bocchia M, Baroni CD, Martelli M, Falini B, Sabattini E, Gherlinzoni F, Amadori S, Poggi S, Mazza P. Anaplastic large cell lymphoma (CD30+/Ki-1+): results of a prospective clinico-pathological study of 69 cases. Br J Haematol 1994; 86: 513-23.
22. Lee SC, Kueh YK, Lehnert M, Chong SM, Tan YO, Wong J. Characteristics and prognosis of KI-1 positive anaplastic large cell lymphoma in Asians. Aust N Z J Med 1998; 28: 790-4.
23. Lin CN, Hou CC, Hwang WS, Chuang SS. Anaplastic large cell lymphoma-a rare disorder in southern Taiwan. Leuk Lymphoma 2003; 44: 1727-31.
24. NPM/ALK expression. Am J Surg Pathol 1997; 21: 1420-32.
25. Kinney MC, Kadin ME. The pathologic and clinical spectrum of anaplastic large cell lymphoma and correlation with ALK gene dysregulation. Am J Clin Pathol 1999; 111 (Suppl 1): 56-67.
26. ten Berge RL, Dukers DF, Oudejans JJ, Pulford K, Ossenkoppele GJ, de Jong D, Misere JF, Meijer CJ. Adverse effects of activated cytotoxic T-lymphocytes on the clinical outcome of nodal anaplastic large cell lymphoma. Blood 1999; 93: 2688-96.
27. ten Berge RL, Oudejans JJ, Ossenkoppele GJ, Pulford K, Willemze R, Falini B, Chott A, Meijer CJ. ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination. J Clin Pathol 2000; 53: 445-50.
28. ten Berge RL, de Bruin PC, Oudejans JJ, Ossenkoppele GJ, van der Valk P, Meijer CJ. ALK-negative anaplastic large-cell lymphoma demonstrates similar poor prognosis to peripheral T-cell lymphoma, unspecified. Histopathology 2003; 43: 462-9.
29. Suzuki R, Kagami Y, Takeuchi K, Kami M, Okamoto M, Ichinohasama R, Mori N, Kojima M, Yoshino T, Yamabe H, Shiota M, Mori S, Ogura M, Hamajima N, Seto M, Suchi T, Morishima Y, Nakamura S. Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype. Blood 2000; 96: 2993-3000.
30. Lopez-Guillermo A, Cid J, Salar A, Lopez A, Montalban C, Castrillo JM, Gonzalez M, Ribera JM, Brunet S, Garcia-Conde J, Fernandez de Sevilla A, Bosch F, Montserrat E. Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the REAL classification. Ann Oncol 1998; 9: 849-55.
31. de Bruin PC, Noorduyn AL, van der Valk P, van Heerde P, van Diest PJ, van de Sandt MM, Ossenkoppele GJ, Meijer CJ. Noncutaneous T-cell lymphomas. Recognition of a lymphoma type (large cell anaplastic) with a relatively favorable prognosis. Cancer 1993; 71: 2604-12.